Novira Therapeutics, Inc., a Radnor, Pennsylvania-based drug discovery company developing therapeutics for the treatment of viral diseases, including HBV and HIV, has completed a second round of seed financing.
The round was led by three Philadelphia-based angel groups, including Delaware Crossing Investor Group, the Mid-Atlantic Angel Group Fund II and Robin Hood Ventures. Initial investor BioAdvance also participated in the round.
This funding, which brings the company’s early financing to approximately $2.5m, with another $1.0m obtained in grants, will enable Novira to advance its novel capsid assembly inhibition compounds that target the Hepatitis B virus (HBV).
In conjunction with the financing, Gregory Harriman, M.D., member at Robin Hood Ventures, will join the company’s board of directors. Karen Griffith Gryga, Executive Director of the Mid-Atlantic Angel Group (MAG) Funds (I & II), will take a seat as a board observer.
Novira’s management team includes Osvaldo (Lalo) Flores, PhD, Chief Scientific Officer and co-Founder, J. David Owens, Chief Business Officer, Ali Munawar, Vice President, Research Operations, co-Founder, and George Hartman, PhD, Vice President, Chemistry, co-Founder.